|2.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
|3.||Overactive Urinary Bladder (Overactive Bladder)
|1.||Yokoyama, Osamu: 10 articles (07/2015 - 04/2010)|
|2.||Weiss, Jeffrey P: 10 articles (04/2015 - 04/2006)|
|3.||Oelke, Matthias: 10 articles (01/2015 - 01/2007)|
|4.||Johnson, Theodore M: 10 articles (11/2013 - 07/2003)|
|5.||Nørgaard, Jens Peter: 7 articles (05/2015 - 07/2007)|
|6.||Asplund, Ragnar: 7 articles (01/2007 - 08/2002)|
|7.||Hirayama, Akihide: 6 articles (10/2014 - 06/2005)|
|8.||Fujimoto, Kiyohide: 6 articles (10/2014 - 06/2005)|
|9.||Roehrborn, Claus G: 6 articles (10/2014 - 08/2006)|
|10.||Michel, Martin C: 6 articles (07/2013 - 09/2005)|
|1.||Deamino Arginine Vasopressin (Desmopressin)FDA LinkGeneric
12/01/2005 - "The mean frequency of nocturia was 6.1 before desmopressin and most (86%) patients had an improvement in nocturia within 1-12 weeks of treatment with desmopressin. "
05/01/1995 - "The purpose of the present study was to assess the efficacy of desmopressin in patients with PD with significant nocturia. "
01/01/2013 - "To compare efficacy of desmopressin for treatment of nocturia between patients with normal and high nocturnal bladder capacity index (NBCi). "
09/01/2013 - "Treatment with 50 μg desmopressin, the minimum effective dose, provided sustained improvement of nocturia throughout the study and meaningful benefits to patients with an improved safety profile."
09/01/2013 - "Previous studies suggest a lower dose of desmopressin orally disintegrating tablet may be effective in females compared to males with nocturia. "
05/01/2013 - "Among patients with nocturia improved by naftopidil, IIEF5 total score was significantly changed in the group with IPSS nocturia score ≤1 as compared to the group with IPSS nocturia score ≥2 per night (P = 0.038). "
01/01/2011 - "Men with high slow stream score and unsatisfactory improvement in nocturia may benefit from dose escalation of naftopidil."
01/01/2007 - "Improvement of nocturia and incomplete emptying by naftopidil contributed to improvement in QOL, odds ratio between the good response group and poor response group were 3.6 and 2.3, respectively. "
03/01/2015 - "Evening dosing of naftopidil seems to be more effective in treating nocturia in male patients with lower urinary tract symptoms."
04/01/2010 - "In conclusion, naftopidil appears to be an effective agent not only for nocturia and other urinary storage symptoms, but also for improving the quality of sleep."
|3.||quinuclidin- 3'- yl- 1- phenyl- 1,2,3,4- tetrahydroisoquinoline- 2- carboxylate monosuccinate (solifenacin)FDA Link
08/01/2006 - "Data from these trials show that solifenacin 5 and 10 mg once daily is significantly more effective than placebo at reducing urgency, incontinence, micturition frequency and nocturia and at increasing volume voided per micturition. "
12/01/2009 - "Solifenacin vs. placebo significantly improved daily episodes of urgency, incontinence and frequency but not nocturia. "
07/01/2007 - "Solifenacin significantly improved nocturia symptoms only in OAB patients without NP."
09/01/2005 - "Solifenacin significantly improved urgency, frequency, and nocturia symptoms and increased volume voided in OAB dry patients."
01/01/2015 - "Patients unsatisfied by therapy with solifenacin 5 mg/ day initially had more severe symptoms of the disease - significantly more urgency frequency, incontinence episodes, and nocturia. "
|4.||tamsulosin (Flomax)FDA LinkGeneric
05/01/2014 - "The α1-adrenoceptor antagonist tamsulosin significantly improved nocturia and sleep quality as well as LUTS in women with low Qmax."
05/01/2014 - "We assessed the effects of the α1-adrenoceptor antagonist, tamsulosin, on nocturia and quality of sleep, for the treatment of lower urinary tract symptoms (LUTS) in women with a maximal flow rate (Qmax) less than 15 mL/sec. From January 2008 to December 2009, women with LUTS [Qmax ≤ 15 mL/s, International Prostate Symptom Score (IPSS) ≥ 8] and nocturia (void/night ≥ 1) were selected for this study. "
11/01/2008 - "The primary purpose of this study was the improvement of nocturia in patients with a poor response to tamsulosin. "
10/01/2014 - "Reduction in nocturia score with combination therapy was significantly (p ≤ 0.01) better than tamsulosin monotherapy across all baseline subgroups tested, except for men with previous 5ARI use. "
05/01/2014 - "The α1 adrenoceptor antagonist tamsulosin for the treatment of voiding symptoms improves nocturia and sleep quality in women."
|5.||KMD 3213FDA Link
10/01/2014 - "Consistent and significant improvement of nighttime voiding frequency (nocturia) with silodosin in men with LUTS suggestive of BPH: pooled analysis of three randomized, placebo-controlled, double-blind phase III studies."
01/01/2010 - "Compared with placebo, silodosin significantly improved nocturia within 1 week (silodosin, -0.5 ± 1.07 versus placebo, -0.3 ± 1.05; P = 0.009) and all other symptoms within 3 to 4 days (P < 0.01). "
01/01/2010 - "Decrease in score from baseline (mean ± standard deviation) to last observation was significantly greater with silodosin than with placebo for all symptoms (P < 0.005); symptom improvement with silodosin (versus placebo) was greatest for weak stream (silodosin, -1.1 ± 1.4 versus placebo, -0.5 ± 1.2; P < 0.0001) and smallest for nocturia (silodosin, -0.6 ± 1.1 versus placebo, -0.4 ± 1.2; P = 0.0037). "
01/01/2014 - "Silodosin is effective in reducing BPH/LUTS, including nocturia and shows little cardiovascular adverse events. "
10/01/2014 - "Although a weak impact on nocturia is already known from α-adrenoceptor antagonists without subtype selectivity, the individual placebo-controlled studies and the pooled data analysis showed that the α1A-adrenoceptor subtype-selective antagonist silodosin consistently and significantly improves nocturia in men with LUTS/BPH."
|6.||tolterodine (Detrol)FDA Link
01/01/2014 - "Tolterodine ER resulted effective in reducing frequency urgency and nocturia and urinary leakage in male patients with OAB/storage LUTS. "
01/01/2007 - "Episodes of urgency, incontinence, daytime frequency and nocturia and responses to the patient perception of bladder condition scale, the urgency perception scale, and visual analog scales of limitations in daily life and of treatment satisfaction were evaluated in 3,824 OAB patients at baseline and during 9 months treatment with tolterodine ER (4 mg q.d.) in an open-label, observational study. "
10/01/2007 - "Although women taking tolterodine ER 4 mg had a consistently greater increase in mean voided volume/void and consistent decreases in incontinence episodes/24 h, urgency episodes/24 h and episodes of nocturia/24 h, this was not statistically significant. "
06/01/1999 - "According to micturition charts, urinary frequency, nocturia, and leakage episodes decreased significantly after tolterodine treatment, whereas average urine volume per day and average voided volume did not change significantly. "
06/01/1999 - "The patients were contacted by telephone 1 week after visit 2. Tolterodine was increased to 2 mg bid if the patient had incomplete improvement at either the initial phone call or during visit 3. Evaluation criteria were daily micturition charts including urinary frequency, nocturia, leakage episodes, average urine volume per day, and average voided volume. "
06/01/2013 - "Imidafenacin was effective in OAB patients with urgency and nocturia. "
09/01/2012 - "Administration of imidafenacin at 0.1-0.2 mg once daily before sleeping was safe and effective for the treatment of OAB with the main symptom of nocturia."
01/01/2012 - "We conclude that imidafenacin is an effective and safe drug for nocturia in patients with OAB."
01/01/2012 - "The efficacy of imidafenacin on nocturia is attributable to an increase in bladder capacity and a decrease in nocturnal urine volume. "
09/01/2013 - "Imidafenacin, an antimuscarinic agent, improves nocturia and reduces nocturnal urine volume."
|8.||Furosemide (Lasix)FDA LinkGeneric
05/01/2012 - "Both furosemide and GJG significantly improved the nocturia score in the I-PSS, the I-PSS Quality of Life (QOL) score, actual nocturnal frequency and hours of undisturbed sleep compared with those at baseline. "
02/01/1998 - "Of patients on active treatment, seven of 19 had a reduction in night-time frequency of > or = 1, compared with only one of 20 on placebo, and 14 of 21 felt that frusemide had helped their nocturia, compared with only five of 22 on placebo. "
05/01/2012 - "Furosemide treatment definitively improved nocturia with nocturnal polyuria. "
03/01/2011 - "Staggered furosemide and desmopressin provide an effective and well-tolerated treatment for nocturia in the elderly."
09/01/2010 - "Four-week treatment with frusemide plus doxazosin was safe and effective for nocturia in patients with BPH/LUTS."
|9.||dutasteride (Avodart)FDA Link
10/01/2014 - "After 24 months of treatment, dutasteride treatment provided significantly greater improvements in nocturia, and less worsening, compared with placebo, primarily in subjects with two or three nocturia episodes per night. "
09/01/2012 - "Among OAB patients, dutasteride significantly improved urgency and urgency incontinence but not nocturia. "
09/01/2013 - "Additional administration of dutasteride to patients with alpha-1 blocker-resistant BPH led to improvements in all voiding and storage symptoms except nocturia, and showed no correlation between the prostate volume reduction rates and improvement in LUTS."
10/01/2014 - "Also at month 24, dutasteride therapy resulted in a greater proportion of subjects with nocturia improvement compared with placebo (p ≤ 0.05), with the largest treatment group differences in subjects with a baseline nocturia score of 2 or 3. Among patients with significant nocturia at baseline (score ≥ 2), significantly more subjects with dutasteride versus placebo had a score <2 at month 24 (26 vs. 19 %, p < 0.001). "
10/01/2014 - "Reduction in nocturia was significantly better with dutasteride than with placebo across all baseline subgroups tested (p ≤ 0.05). "
07/01/2010 - "Thus, melatonin could be beneficial for nocturia via a central nervous system effect."
03/01/2004 - "Melatonin treatment is associated with a significant nocturia response rate, improvement in nocturia related bother and a good adverse effect profile. "
02/01/2010 - "An improvement in nocturia and nocturia bother score have been shown after administration of oral melatonin. "
03/01/2004 - "This study was designed to investigate melatonin as a potential treatment for nocturia associated with bladder outflow obstruction in older men. "
06/01/2014 - "Melatonin secretion is significantly and inversely associated with nocturia in a general elderly population."
06/01/2007 - "The most predictable symptom for improvement in QOL after treatment was the improvement in the bother score for nocturia (F test; p <0.01). "
02/01/2004 - "The effects were assessed by questionnaire before and after treatment as excellent (nocturia disappeared or decreased by 2 or more voids/night), improved (nocturia decreased by 1 void/night), unchanged, or worsened (nocturia increased). "
03/01/2014 - "The parameters always significantly improved concerned: number of incontinence episodes (decreased from 64% to 86% after treatment versus before treatment), quality of life (P≤0.001), severity of irritative symptoms (decreased by more than 50% after treatment versus before treatment), and nocturia (P=0.035 to P<0.001). "
12/01/2010 - "Significant improvement (P < 0.01) was noted in all the following parameters after treatment: the number of nocturia events decreased from 4.2 ± 2.4 to 2.2 ± 1.0, HUS increased from (1.8 ± 0.7) h to (3.0 ± 1.4) h, N-QOL score raised from 30 ± 10 to 40 ± 7, IPSS decreased from 23 ± 5 to 8 ± 5, and QOL score fell down from 4.4 ± 0.7 to 1.5 ± 1.0. "
09/01/2010 - "Total IPSS and QOL index in patients with previous treatment were significantly improved after treatment, with significant improvements in the "incomplete emptying,""poor flow" and "nocturia" parameters of IPSS. "
|2.||Drug Therapy (Chemotherapy)
07/01/2013 - "Efficacy of adding behavioural treatment or antimuscarinic drug therapy to α-blocker therapy in men with nocturia."
04/01/2015 - "Given the lack of known effective pharmacotherapy for low bladder volume, the first attempt nocturia treatment could focus on volume reduction."
04/01/2014 - "Management of nocturia: the role of antidiuretic pharmacotherapy."
07/01/2013 - "Both behavioural treatment and drug therapy reduced nocturia in men with ≥1 episode of nocturia/night when added to α-blocker therapy. "
07/01/2013 - "Among those with ≥1 nocturia episode, behavioural treatment reduced nightly nocturia by a mean of 0.97 episodes and was significantly more effective than drug therapy (mean reduction = 0.56 episodes; P = 0.01). "
08/01/2003 - "Parathyroidectomy resulted in significant improvement of PHPT-associated symptoms of fatigue, weight loss, nocturia, bone pain, constipation, and major depression (P<.05). "
10/01/1991 - "Our study documents the following: (1) only 2 of 103 (2%) patients referred for parathyroidectomy had "true" asymptomatic hyperparathyroidism; (2) only symptoms of fatigue, bone pain, and weight loss correlated with the degree of hypercalcemia, whereas muscular weakness, psychiatric symptoms, nocturia, polyuria, recent memory loss, constipation, and nephrolithiasis did not; (3) only 1 of 15 patients who were referred as asymptomatic were truly asymptomatic after more thorough questioning, and all 14 improved following parathyroidectomy; (4) 81% of the patients who were referred with symptoms improved following parathyroidectomy; and (5) permanent complications occurred in only 4 patients. "
04/01/2011 - "Oral administration of desmopressin is an effective and well-tolerated treatment for nocturia in elderly men."
09/01/1990 - "The major symptoms were dizziness, palpitation, chest press, malaise, remission in memory, nocturia, amaurosis and Adams-Stokes syndrome, etc. Self-comparison was taken, Xin Bao was given 2-10 tablets 2 or 3 times a day by oral administration for 2 months. "
01/01/1992 - "With the urethral approach, 77 patients out of 100 presented an improvement in their symptoms, nycturia improved in 53; urine flow improved in 28; the urine residue was decreased in 40 and the vesical catheter could be removed in 10 out of 16 patients who required it previously. "
01/01/1992 - "In the group of 100 patients treated rectally, the subjective symptoms and nycturia improved in 76; urine flow improved in 63, postmicturition residue decreased in 32 and the vesical catheter could be removed in 5 out of 8 patients. "
06/01/2007 - "Descriptive statistics and Chi-square analysis were performed to describe the sample, use of nightly sedation, and to compare the incidence of nocturia for 4 consecutive nights after catheter removal in subjects who had SDB symptoms of OSA with those who did not have SDB symptoms of OSA. "
06/01/2007 - "Data on voiding patterns and nocturia were collected for 4 nights after catheter removal. "
01/01/2006 - "Postoperative urinary symptoms developed with 59% reporting the development of nocturia, 18% developed stress incontinence and one patient required a permanent catheter. "